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Conclusions: Experience with the MitraClip in patients with a dilated left ventricle
suggests that the procedure is safe and feasible in most patients. Mortality and heart
failure-related hospital rates are low. This therapy may be an alternative to surgery in this
high-risk group of patients.
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Background: Left ventricle (LV) remodeling after anterior wall myocardial infarction leads
to increased LV volumes, myocardial stress and ultimately congestive heart failure (CHF).
Treatment options are limited for these high morbidity and mortality risk population.
Methods: The study included 39 patients with ischemic CHF class II-IV (NYHA),
akinetic or dyskinetic wall abnormality, ejection fraction between 15 and 40% and no
revascularization options were enrolled in 14 U.S. and European sites. The device was
deployed into the left ventricle apex to partition off the damaged myocardium. Warfarin
and ASA treatment for 1-year post implant. All events were adjudicated and CT, EKG and
echo data were analyzed by independent core labs.
Results: End-diastolic volume was 127.5cc pre-procedure, 106.7cc at 6-month and
114.7cc at 2 years by echo (p0.74 6M vs 2Y). There were no strokes and worsening
CHF or death occurred in 32.9% (per Protocol n34) or 29.5% (treated pts, n31) of
patients at 2 years. Average NYHA class reduced from 2.6 to 1.9 with 87% of patients
reporting improvement in symptoms at 12 months. Adjudication of 3-year clinical events
will be completed in July 2012 and will be available for presentation.
Conclusions: Sustained 2-year improvement in symptoms and LV volume was observed
after PVR using the ParachuteTM device in patients with ischemic CHF and anterior LV
dilatation. Three-year clinical data will provide important insights into long-term safety of
this novel therapy.
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Background: Recent studies have raised major concerns about an increased risk of
cerebrovascular events (CVE) following transcatheter aortic valve implantation (TAVI).
The objective of this study was to evaluate the timing, predictive factors and prognostic
value of CVE following TAVI.
Methods: A total of 1061 consecutive patients who underwent TAVI with a balloon-
(64%) or a self- (36%) expandable valve in 5 centers were included. CVEs were defined
using the VARC criteria and further classified according to timing with respect to the
TAVI procedure as acute (24 hours), subacute (1 to 30 days), and late (30 days). All
baseline, procedural, and follow-up data were prospectively recorded.
Results: CVEs occurred in 54 patients (5.1%; stroke: 4.2%, TIA: 0.9%) within 30 days
following TAVI, and were acute and subacute in 54% and 46% of cases, respectively. The
predictors of acute CVEs were balloon postdilation (BPD) of the valve prosthesis (OR:
2.46, 95% CI: 1.07-5.67) and valve dislodgment/embolization (OR: 4.36, 95% CI:
1.21-15.69); new-onset atrial fibrillation [NOAF] (OR 2.72, 95% CI 1.10-6.73) was the
only predictor of subactute CVEs. Late CVEs occurred in 35 patients (3.6%; stroke: 2.1%,
TIA: 1.5%) at a median follow-up of 12 (3-23) months. The independent predictors of late
CVEs were chronic AF (HR: 2.62, 95% CI 1.34-5.11) and peripheral vascular disease
(HR: 2.07, 95% CI 1.05-4.08). Major stroke was independently associated with 30-day
(OR 7.43, 95% CI 2.45-22.53) and late (HR: 1.75, 95 CI% 1.01-3.03) mortality.
Conclusions: In a large cohort of patients undergoing TAVI, the rate of acute and
subacute CVEs was 2.7% and 2.4%, respectively. While mechanical factors such as
further stretching of the valve prosthesis with BPD and valve embolization were the
predictors of acute CVEs, atrial arrhythmias (NOAF) determined a higher risk for
subacute events. Late events were mainly determined by chronic AF and peripheral
vascular disease. The occurrence of major stroke was associated with an increased early
and late mortality. These results provide important insights for the implementation of
preventive measures for CVEs following TAVI.
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Background: The predictors of persistent(vs transient or absent)left bundle branch block
(LBBB)after transcatheter aortic valve implantation(TAVI)with a balloon-expandable
valve(BEV)and its clinical consequences are unknown. The aim of this study was to
evaluate the predictors and prognostic value of new-onset persistent LBBB in patients
undergoing TAVI with a BEV.
Methods: A total of 202 consecutive patients with no baseline ventricular conduction
disturbances or previous permanent pacemaker implantation (PPI) who underwent TAVI
with a BEV were included. Patients were on continuous ECG monitoring during
hospitalization and 12-lead ECG was performed daily until hospital discharge. No patient
was lost at a median follow-up of 12 (6-24) months, and ECG tracing was available in
97% of patients. The criteria for PPI were limited to the occurrence of high degree
atrioventricular block (AVB) or severe symptomatic bradycardia.
Results: New-onset LBBB was observed in 61 patients (30.2%) immediately after TAVI,
and had resolved in 37.7% and 57.3 % of them at hospital discharge and at 6 to 12-months
follow-up, respectively. Baseline QRS duration (p0.037) and prosthesis ventricular
depth (p0.017) were independent predictors of persistent LBBB. Persistent LBBB at
hospital discharge was associated with a decrease in left ventricular ejection fraction
(p0.001) and poorer functional status (p0.034) at 1-year follow-up. Patients with
persistent LBBB and no PPI at hospital discharge had a higher incidence of syncope
(16.0% vs. 0.7%, p0.001) and complete AVB requiring PPI (20.0% vs. 0.7%,
p0.001), but not of global mortality, cardiac mortality or sudden death during the
follow-up period (p0.20 for all). New-onset LBBB was the only factor associated with
PPI following TAVI (p0.001).
Conclusions: Up to 30% of the patients with no prior conduction disturbances developed
new LBBB following TAVI with a BEV, although it was transient in more than one third of
them. Longer baseline QRS duration and a more ventricular positioning of the prosthesis were
associated with a higher rate of persistent LBBB, which in turn determined a higher risk for
complete AVB and PPI but not mortality or sudden death at 1-year follow-up.
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Background: A significant perivalvular aortic regurgitation (AR) is observed in 10-20%
after a successful TAVI procedure. The prognostic value and the predictors of such
TUESDAY, OCTOBER 23, 10:30 AM–12:30 PM www.jacc.tctabstracts2012.com
B28 JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/ORAL/Transcatheter Aortic Valve Replacement I
O
R
A
L
S
complication in Balloon-expendable (BE) and Self-expendable (SE) TAVI procedures
remain unclear.
Methods: 2,769 patients consecutive with a successful procedure and a predischarge
transthoracic echocardiography (TTE) were enrolled in 33 centers. Mean follow-up was
302164 days.
Results: Mean age was 837 years; 49% were female and logistic EuroSCORE was
21.513.8. BE and SE devices was implanted in 67.6% (n1872) and 32.4% (n897),
respectively. Approaches were femoral (75.4%) or non femoral: subclavian (5.6%),
transapical (17.2%) or transaortic (1.8%). A perivalvular AR2 was observed in 14.9%.
Its occurrence was 2 fold higher in SE (19.8%) than in BE-TAVI procedures (12.2%,
p0.0001). This remained significant in multivariate analysis (adjusted HR2.01,
p0.0001). A perivalvular AR2 was associated with a mortality at 1 year (24.2%) twice
higher than in patients without AR (11.9%) (p0.0001). This figure was similar for BE
(27.1% vs 12.0%) and SE-TAVI (20.5% vs 11.8%) procedures. By multivariate analysis,
a perivalvular AR2 was the strongest predictor of 1 year mortality (ad. HR2.35
[1.75-3.15]; p0.0001). This figure was similar for BE (ad. HR2.68) and SE-TAVI (ad.
HR2.10) procedures. For BE-TAVI procedures, male gender (ad. HR1.66, p0.001),
a device diameter/aortic annulus diameter Ratio 1.1 (ad. HR1.83, p0.0001) and a
femoral approach (ad. HR1.70, p0.006) were the 3 major independent predictors of
AR2. For SE-TAVI procedures, male gender (ad. HR1.61, p0.01) and a femoral
approach (ad.HR2.1, p0.008) were 2 independent predictors of AR2. Importantly,
device diameter/aortic annulus diameter Ratio was not a predictor of AR for SE-TAVI
procedures.
Conclusions: Post-procedural perivalvular AR2 was observed in 15% of successful
TAVI procedures. Its occurrence doubled the 1-year mortality rate and was the strongest
and independent predictor of 1-year mortality for both BE and SE-TAVI procedures.
Analysis of predictors of AR suggests that device-type and procedural characteristics may
impact the occurrence of AR.
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Background: The presence of mitral regurgitation (MR) is an independent predictor of
mortality after conventional aortic valve replacement for aortic stenosis. The predictive
value of pre-procedural MR on clinical outcome after TAVI is unknown.
Methods: 3,195 consecutive patients were enrolled in 33 centres. MR was graded
according to pre-procedural transthoracic echocardiography (TTE) as none/trivial(0),
mild(1), moderate(2), moderate-to-severe(3), or severe(4). The mean age was
827 years; 49% were female and mean logistic EuroSCORE was 21.914.3. Balloon
(BE) and self-expendable (SE) devices were implanted in 66.9% and 33.1% of patients,
respectively. Approaches were transarterial (transfemoral: 74.6%; subclavian: 5.8%),
transapical (17.8%), and transaortic (1.8%).
Results: Pre-procedural TTE showed no MR in 32% of cases, a grade 1 MR in 46% of
cases, a grade 2 MR in 20% of cases and a grade 3-4 in 2% of cases. Procedural success
rate was 96.9%. Actuarial 1 year mortality was 19.5%. By univariate analysis, pre-
procedural MR grade2, MR Grade1 and MR Grade0 were associated with a 1 year
mortality of 24.0%, 20.1% and 15.8%, respectively (p0.002). By multivariate analysis,
4 independent baseline characteristics were associated with preprocedural MR: a higer
Logistic EuroSCORE (p0.0001), a lower ejection fraction (p0.0002), a higher NYHA
class (p0.0007), and female gender (p0.001). By multivariate Cox analysis, indepen-
dent predictors of one-year mortality were: logistic EuroSCORE (p0.0001), NYHA
class (p0.0001) and transapical approach (p0.0005). The presence of preprocedural
MR was not significantly associated with 1-year mortality (p0.31). Results did not differ
when analyses were restricted only to BE or only to SE devices.
Conclusions: A mild(grade1) or a moderate(grade 2) MR preprocedural is associated
with a higher 1-year mortality after TAVI. However, since preprocedural MR is
associated with a higher NYHA class or a higher logistic Euroscore, pre-procedural MR
is not an independent predictor of mortality. These findings suggest that, in itself, the
presence of a mild or a moderate MR should not refrain from performing TAVI and
should not impact the type of valve to be used.
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Background: The Placement of Aortic Transcatheter Valves (PARTNER) trial Cohort A
demonstrated similar survival after transcatheter and surgical aortic valve replacement
(TAVR and SAVR, respectively) in high-risk operable patients with symptomatic, severe
aortic stenosis (AS). The impact of valve replacement technique on left ventricular (LV)
function and the effects of LV dysfunction on clinical outcomes are unknown.
Methods: The PARTNER trial randomized high-risk patients with severe AS to TAVR
or SAVR. Echocardiographic evaluation was performed at baseline, hospital discharge,
1-, 6-, and 12-months. Patients were stratified by the presence of LV dysfunction
(LVEF50%).
Results: In patients with LV dysfunction (N215), mean LV ejection fraction (LVEF)
increased from 369 to 4912% 1-year after TAVR and from 389 to 4912% after
SAVR (pNS). At 1-year, LVEF was unchanged in patients with preserved LV function
(N454) in both treatment groups. All-cause mortality was similar for TAVR and SAVR
at 30-days and 1-year regardless of baseline LV function and valve replacement technique
(Figure). Rates of repeat hospitalization at 1-year follow-up were comparable with TAVR
and SAVR in patients with reduced (25.6 vs17.1%, pNS) and preserved (11.7 vs 14.8%,
pNS) LV function, as were functional class and 6-minute walk test.
Conclusions: In high-risk patients with severe AS and LV dysfunction, improvements in
LVEF were similar after TAVR and SAVR. Mortality rates were comparable between
valve replacement techniques regardless of LV function.
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Background: The outcomes of severe aortic stenosis (AS) patients with chronic
obstructive pulmonary disease (COPD) undergoing transcatheter aortic valve replacement
(TAVR) have not been systematically studied. The present study aimed to evaluate the
impact of COPD on the outcome of patients treated for severe AS across all treatment
modalities.
Methods: All patients included in the PARTNER trial and who underwent TAVR,
including continued access patients, (n1938) were evaluated for outcome according to
COPD severity, stratified into no COPD, non-oxygen-dependent (non-O2 dep) COPD and
oxygen-dependent (O2 dep) COPD. Outcomes of COPD patients in the different study
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